Investigational drug · Phase 3
Mosliciguat
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Pulmonary Hypertension, Interstitial Lung Disease, Vascular Diseases.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 11, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "Mosliciguat"
First trial start
2024
Oct 29, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Mosliciguat", any sponsor or status.
Conditions studied
As listed on its trial records.
- Pulmonary Hypertension
- Interstitial Lung Disease
- Vascular Diseases
- Cardiovascular Diseases
- Fibrosis
- Lung Diseases
Approved drugs for the same conditions: High blood pressure (hypertension) · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "Mosliciguat" as an intervention, largest first.
- A Phase 3 Trial of Inhaled Mosliciguat in PH-ILD (PHrontier)Pivotal-lookingRecruiting
Pulmovant, Inc.Industry
NCT07816185 · 376 participants (planned) · Start Aug 31, 2026 · Primary completion Jan 28, 2029
Drug: Mosliciguat; Placebo · For: Pulmonary Hypertension; Interstitial Lung Disease; Vascular Diseases and 2 more
Sites: Kissimmee, Florida; Louisville, Kentucky; Bend, Oregon
- A Study of Mosliciguat in PH-ILDPivotal-lookingActive, not recruiting
Pulmovant, Inc.Industry
NCT06635850 · 135 participants · Start Oct 29, 2024 · Primary completion May 26, 2026
Drug: Mosliciguat; Placebo · For: Pulmonary Hypertension; Interstitial Lung Disease; Lung Diseases and 3 more
Sites: Phoenix, Arizona; Los Angeles, California; Sacramento, California · 85 sites in all
Pulmovant, Inc.Industry
NCT07333183 · 20 participants (planned) · Start Dec 23, 2025 · Primary completion Dec 2026
Drug: inhaled mosliciguat · For: Pulmonary Hypertension; Interstitial Lung Disease (ILD); Lung Diseases and 3 more
Sites: Santa Barbara, California; Torrance, California; Kissimmee, Florida · 13 sites in all
Pulmovant, Inc.Industry
NCT07185321 · 8 participants · Start Jun 10, 2025 · Primary completion Jun 30, 2025
Drug: Mosliciguat; 14C mosliciguat · For: Healthy Volunteer
Sites: Baltimore, Maryland
Newest research
PubMed records naming it or its code names, newest first.
- Safety and pharmacokinetics of mosliciguat, a new, inhaled soluble guanylate cyclase activator, in healthy adult subjects.
Nagelschmitz J, Saleh S, Ligges S, et al. · Br J Clin Pharmacol 2026
- Phase 1b ATMOS trial of the inhaled sGC activator mosliciguat in patients with PAH/CTEPH.
Ghofrani HA, Leuchte HH, Al-Hiti H, et al. · Thorax 2026
- Pharmacokinetics and Lung Deposition After Administration of Inhaled Mosliciguat (BAY 1237592): Results from Randomized Phase I Studies in Healthy Men.
Saleh S, Mundry T, Nagelschmitz J, et al. · Clin Pharmacokinet 2025
- The 10th International Conference on cGMP 2022: recent trends in cGMP research and development-meeting report.
Friebe A, Kraehling JR, Russwurm M, et al. · Naunyn Schmiedebergs Arch Pharmacol 2023
- Inhaled mosliciguat (BAY 1237592): targeting pulmonary vasculature via activating apo-sGC.
Becker-Pelster EM, Hahn MG, Delbeck M, et al. · Respir Res 2022
Also in development for Pulmonary Hypertension
- INS1009Treprostinil PalmitilPhase 37 trials
Insmed Incorporated · Interstitial Lung Disease, Pulmonary Hypertension, Pulmonary Arterial Hypertension
- TNX-103Phase 33 trials
Tenax Therapeutics, Inc. · Pulmonary Hypertension Associated With HFpEF, Pulmonary Hypertension
- RalinepagAPD811Phase 32 trials
United Therapeutics · PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension
- HS235Phase 22 trials
35Pharma Inc., a GSK company · Pulmonary Arterial Hypertension, Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
- TX000045Phase 22 trials
Tectonic Therapeutic · Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction, Hypertension, Pulmonary
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.